Skip to main content
Cureus logoLink to Cureus
. 2026 May 8;18(5):e108470. doi: 10.7759/cureus.108470

Granulomatosis With Polyangiitis Presenting as Pulmonary Masses With Coexisting Infection: A Diagnostic Challenge Leading to Life-Threatening Pulmonary-Renal Syndrome

Ibrahim Saleh 1,✉, Mostafa Abdelaty 2, Mohamed Gendia 3, Noha Abdelkarim 3, Ammar Ahmed 3
Editors: Alexander Muacevic, John R Adler
PMCID: PMC13242621  PMID: 42261502

Abstract

Granulomatosis with polyangiitis (GPA) is an antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis that can mimic infection and malignancy, posing a significant diagnostic challenge. We report the case of a 39-year-old male smoker with a strong family history of lung cancer who presented with fever, weight loss, dyspnea, and hemoptysis. Initial evaluation supported infection, with sputum cultures positive for Pseudomonas aeruginosa and Haemophilus influenzae. Imaging later revealed pulmonary masses suspicious for malignancy. The patient subsequently deteriorated with massive hemoptysis and acute kidney injury, requiring ICU admission, mechanical ventilation, blood transfusion, and dialysis. Further investigations demonstrated proteinase 3-ANCA positivity and diffuse alveolar hemorrhage on bronchoalveolar lavage, confirming GPA. Treatment with pulse corticosteroids, IV cyclophosphamide, and plasma exchange resulted in marked clinical recovery. This case underscores the significant diagnostic challenge posed by the overlap between infection, malignancy, and ANCA-associated vasculitis, highlighting the importance of early recognition and timely initiation of immunosuppressive therapy.

Keywords: anca-associated vasculitis, diffuse alveolar hemorrhage, granulomatosis with polyangiitis, lung mass, pulmonary-renal syndrome

Introduction

Granulomatosis with polyangiitis (GPA) is a necrotizing small-vessel vasculitis characterized by granulomatous inflammation involving the respiratory tract and kidneys [1,2]. It is commonly associated with proteinase 3-antineutrophil cytoplasmic antibodies (PR3-ANCAs) and can present with a wide spectrum of clinical manifestations, ranging from localized disease to life-threatening systemic involvement. Pulmonary involvement is common and may include nodules, masses, or diffuse alveolar hemorrhage (DAH), which represents a severe and potentially fatal complication [3,4]. Renal disease typically manifests as rapidly progressive glomerulonephritis [5,6].

In some cases, GPA may mimic malignancy radiologically, particularly when presenting with pulmonary masses in patients with risk factors such as smoking [4]. The coexistence of infection further complicates the clinical picture, creating a significant diagnostic dilemma among infection, malignancy, and vasculitis, which may delay appropriate immunosuppressive therapy.

Case presentation

A 39-year-old male smoker with a significant family history of lung cancer presented with a 20-day history of fever, weight loss, dyspnea, and hemoptysis. Initial investigations suggested an infectious etiology. Sputum cultures grew Pseudomonas aeruginosa and Haemophilus influenzae. However, the lack of significant clinical improvement despite appropriate antimicrobial therapy raised suspicion for an alternative diagnosis. Chest X-ray on admission demonstrated mediastinal widening suspicious for mediastinal masses, without clear pneumonic consolidation (Figure 1).

Figure 1. Chest X-ray on admission showing mediastinal widening suspicious for mediastinal masses, with no definite pneumonic consolidation.

Figure 1

Due to persistent hemoptysis, CT pulmonary angiography was performed, which excluded pulmonary embolism but revealed bilateral pulmonary soft tissue masses (Figure 2).

Figure 2. CT pulmonary angiography showing bilateral pulmonary soft tissue masses with no evidence of pulmonary embolism.

Figure 2

Given the patient’s smoking history and family history, malignancy was strongly suspected. PET-CT demonstrated multiple hypermetabolic lung lesions (Figure 3), while CT abdomen was unremarkable.

Figure 3. PET-CT demonstrating multiple hypermetabolic lung lesions.

Figure 3

Given the radiological findings and clinical context, malignancy remained a strong differential diagnosis at this stage. Further virological screening revealed cytomegalovirus (CMV) viremia (~745 copies/mL), and the patient received antimicrobial therapy, including antiviral coverage with ganciclovir. The patient subsequently deteriorated with massive hemoptysis and a drop in hemoglobin from 11.5 to 7.5 g/dL. He required blood transfusion and ICU admission. Chest X-ray at deterioration showed bilateral diffuse opacification (Figure 4).

Figure 4. Chest X-ray during deterioration showing bilateral diffuse opacification.

Figure 4

He required mechanical ventilation and developed acute kidney injury (creatinine ~400 µmol/L), requiring dialysis. Rheumatological evaluation revealed a vasculitic skin rash (Figure 5).

Figure 5. Clinical image of vasculitic skin rash.

Figure 5

Skin biopsy confirmed leukocytoclastic vasculitis. Laboratory findings demonstrated positive PR3/c-ANCA, low complement C3, and active urinary sediment with red blood cell casts. Bronchoscopy showed diffuse hyperemic mucosa (Figure 6), and bronchoalveolar lavage confirmed DAH with hemosiderin-laden macrophages.

Figure 6. Bronchoscopy showing diffuse hyperemic mucosa.

Figure 6

As the clinical picture evolved with combined pulmonary and renal involvement, a pulmonary-renal syndrome was suspected. A diagnosis of GPA presenting as pulmonary-renal syndrome was established.

The patient received pulse methylprednisolone followed by IV pulse cyclophosphamide [7]. Due to severe disease, seven sessions of plasma exchange were performed [3,8].

The patient improved significantly, with resolution of hemoptysis, successful extubation, and normalization of renal function. Follow-up chest X-ray demonstrated interval resolution of bilateral opacities with clear lung fields (Figure 7).

Figure 7. Follow-up chest X-ray showing interval resolution of bilateral opacities with clear lung fields.

Figure 7

A summary of the clinical course is presented in Table 1.

Table 1. Clinical timeline.

AKI, acute kidney injury; ANCA, antineutrophil cytoplasmic antibody; CMV, cytomegalovirus; GPA, granulomatosis with polyangiitis; PE, pulmonary embolism

Time point Clinical events
Day 0 Admission with fever, weight loss, hemoptysis
Early admission Positive sputum cultures, treated as pneumonia
Early imaging Chest X-ray: mediastinal widening
Day 6 CT pulmonary angiography: no PE, bilateral lung masses
Day 10 PET-CT: multiple hypermetabolic lung lesions
Day 12 CMV viremia detected, ganciclovir started
Day 19 Massive hemoptysis and hemoglobin drop
ICU admission Mechanical ventilation and transfusion
ICU course AKI requiring dialysis
Rheumatology ANCA positive with vasculitic rash
Diagnosis GPA
Treatment Steroids, cyclophosphamide, and plasma exchange
Outcome Recovery and discharge

Discussion

This case illustrates a complex presentation of GPA with overlapping features of infection and malignancy. The presence of confirmed bacterial infection and CMV viremia initially supported an infectious diagnosis, while radiological findings suggested malignancy, particularly in the context of smoking and family history [4]. This overlap contributed to diagnostic uncertainty, a scenario frequently reported in ANCA-associated vasculitis, where overlapping clinical features may obscure early recognition and delay appropriate treatment [4].

The development of pulmonary-renal syndrome with DAH represented the key diagnostic turning point. DAH is a severe manifestation of ANCA-associated vasculitis associated with significant morbidity [3]. The diagnosis was supported by PR3-ANCA positivity and histopathological findings, consistent with established classification criteria [2].

Management required careful balancing between immunosuppressive therapy and infection control. Current guidelines recommend high-dose glucocorticoids combined with cyclophosphamide or rituximab in patients with organ- or life-threatening disease [5,6].

IV pulse cyclophosphamide provides effective disease control with reduced cumulative toxicity [7]. Plasma exchange remains controversial following the PEXIVAS trial but may still be considered in selected patients with severe renal impairment or pulmonary hemorrhage [3,8].

A key diagnostic challenge in this case was distinguishing among infection, malignancy, and vasculitis. While microbiological findings initially supported an infectious etiology, the lack of sustained clinical improvement and the presence of atypical features raised suspicion for alternative diagnoses. Radiological findings suggested malignancy, particularly in the context of smoking history; however, the subsequent development of pulmonary-renal syndrome pointed toward an underlying vasculitic process. This case highlights the importance of maintaining a broad differential diagnosis and integrating clinical, radiological, and laboratory data in complex presentations. In this case, delayed recognition of ANCA-associated vasculitis in the setting of overlapping infectious and malignant features underscores a significant diagnostic challenge, emphasizing the importance of early diagnosis and prompt initiation of immunosuppressive therapy [9].

Conclusions

This case highlights the diagnostic challenge of GPA presenting with overlapping infectious and malignant features, which may lead to significant delays in diagnosis. The coexistence of confirmed infection and radiological findings suggestive of malignancy initially obscured the underlying vasculitic process. The subsequent development of pulmonary-renal syndrome with DAH represented a critical turning point that prompted appropriate diagnostic evaluation. This case underscores the importance of maintaining a high index of suspicion for ANCA-associated vasculitis in patients who fail to respond to appropriate antimicrobial therapy, as early recognition and timely initiation of immunosuppressive treatment are essential for improving clinical outcomes.

Disclosures

Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study.

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Author Contributions

Concept and design:  Ibrahim Saleh, Mohamed Gendia

Drafting of the manuscript:  Ibrahim Saleh, Mostafa Abdelaty, Mohamed Gendia, Noha Abdelkarim, Ammar Ahmed

Critical review of the manuscript for important intellectual content:  Ibrahim Saleh, Mostafa Abdelaty, Mohamed Gendia, Noha Abdelkarim, Ammar Ahmed

Acquisition, analysis, or interpretation of data:  Mostafa Abdelaty, Noha Abdelkarim, Ammar Ahmed

Supervision:  Mostafa Abdelaty, Mohamed Gendia, Noha Abdelkarim, Ammar Ahmed

References

  • 1.2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Jennette JC, Falk RJ, Bacon PA, et al. Arthritis Rheum. 2013;65:1–11. doi: 10.1002/art.37715. [DOI] [PubMed] [Google Scholar]
  • 2.2022 American College of Rheumatology/European Alliance of Associations for rheumatology classification criteria for granulomatosis with polyangiitis. Robson JC, Grayson PC, Ponte C, et al. Arthritis Rheumatol. 2022;74:393–399. doi: 10.1002/art.41986. [DOI] [PubMed] [Google Scholar]
  • 3.Diffuse alveolar haemorrhage in ANCA-associated vasculitis. West S, Arulkumaran N, Ind PW, Pusey CD. Intern Med. 2013;52:5–13. doi: 10.2169/internalmedicine.52.8863. [DOI] [PubMed] [Google Scholar]
  • 4.Pulmonary pattern in systemic vasculitis: granulomatosis, lung cancer or both? Smiyan S, Bernstein Z, Izhik A, et al. Reumatologia. 2022;60:437–443. doi: 10.5114/reum.2022.123673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Kidney Int. 2024;105:0–116. doi: 10.1016/j.kint.2023.10.008. [DOI] [PubMed] [Google Scholar]
  • 6.EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. Ann Rheum Dis. 2024;83:30–47. doi: 10.1136/ard-2022-223764. [DOI] [PubMed] [Google Scholar]
  • 7.Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis: a randomized trial. de Groot K, Harper L, Jayne DR, et al. Ann Intern Med. 2009;150:670–680. doi: 10.7326/0003-4819-150-10-200905190-00004. [DOI] [PubMed] [Google Scholar]
  • 8.Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. Walsh M, Merkel PA, Peh CA, et al. N Engl J Med. 2020;382:622–631. doi: 10.1056/NEJMoa1803537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. McAdoo SP, Medjeral-Thomas N, Gopaluni S, et al. Nephrol Dial Transplant. 2019;34:63–73. doi: 10.1093/ndt/gfx378. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cureus are provided here courtesy of Cureus Inc.

RESOURCES